ATC Group: J01DE51 Cefepime and beta-lactamase inhibitor

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of J01DE51 in the ATC hierarchy

Level Code Title
1 J Antiinfectives for systemic use
2 J01 Antibacterials for systemic use
3 J01D Other beta-lactam antibacterials
4 J01DE Fourth-generation cephalosporins
5 J01DE51

Active ingredients in J01DE51

Active Ingredient Description
Cefepime and Enmetazobactam

Cefepime exerts bactericidal activity by inhibiting peptidoglycan cell wall synthesis as a result of binding to and inhibition of penicillin-binding proteins (PBPs). Enmetazobactam is a penicillanic acid sulfone beta-lactamase inhibitor structurally related to penicillin. Enmetazobactam binds to β-lactamases and prevents the hydrolysis of cefepime. It is active against class A ESBLs.

Related product monographs

Title Information Source Document Type  
EXBLIFEP Powder for concentrate for solution for infusion European Medicines Agency (EU) MPI, EU: SmPC
EXBLIFEP Solution for injection FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Lithuania (LT)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.